Moleculin
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5300 Memorial Dr Ste 950, Houston, Texas...Phone Number
(713) 300-5160Website
www.moleculin.comRevenue
-Stock Symbol
MBRXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Moleculin
Moleculin Biotech is a late-stage clinical pharmaceutical company developing Annamycin (naxtarubicin), a "next-generation" anthracycline, in a pivotal Phase 2/3 MIRACLE trial combined with cytarabine for relapsed/refractory acute myeloid leukemia. Technologies originate from licenses with UT MD Anderson Cancer Center. Interim June 2026 data showed higher remission rates versus control, though not yet statistically significant; final analysis pending across ~282 planned subjects.Explore more
Moleculin Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Moleculin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Moleculin has recently received funding, and reach out quickly before it becomes old news!
Check out if Moleculin is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Moleculin
Product Launch: Get notified when Moleculin launches new products
Click to see if Moleculin had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Moleculin has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Moleculin, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Moleculin recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Moleculin as Masked Content
Find 3 more new buyers
Compare Similar Companies to Moleculin
Compare insights from companies similar to Moleculin, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Moleculin is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Moleculin is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Moleculin.
Moleculin financials insights
Gather financial insights about Moleculin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$1.4M
2016
Stock Offering
$9.2M
Moleculin Tech Stack
A closer look at the technologies used by Moleculin
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Moleculin News & Media
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part AMoleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment.Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-treat basis with no patient exclusions. Both Annamycin treatment arms demonstrated favorable efficacy trends compared with the control arm in patients with relapsed or refractory acute myeloid leuIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Moleculin
Sign Up For FreeTo access detailed company insights
Moleculin Biotech is a late-stage clinical pharmaceutical company developing Annamycin (naxtarubicin), a "next-generation" anthracycline, in a pivotal Phase 2/3 MIRACLE trial combined with cytarabine for relapsed/refractory acute myeloid leukemia. Technologies originate from licenses with UT MD Anderson Cancer Center. Interim June 2026 data showed... Read More
